SK9062003A3 - Substituted triazole diamine derivatives as kinase inhibitors - Google Patents

Substituted triazole diamine derivatives as kinase inhibitors Download PDF

Info

Publication number
SK9062003A3
SK9062003A3 SK906-2003A SK9062003A SK9062003A3 SK 9062003 A3 SK9062003 A3 SK 9062003A3 SK 9062003 A SK9062003 A SK 9062003A SK 9062003 A3 SK9062003 A3 SK 9062003A3
Authority
SK
Slovakia
Prior art keywords
alkyl
group
amino
substituted
substituents independently
Prior art date
Application number
SK906-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Ronghui Lin
Shenlin Huang
Steven K Wetter
Peter J Connolly
Stuart L Emanuel
Robert H Gruninger
Steven A Middleton
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of SK9062003A3 publication Critical patent/SK9062003A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK906-2003A 2000-12-22 2001-12-21 Substituted triazole diamine derivatives as kinase inhibitors SK9062003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25770300P 2000-12-22 2000-12-22
PCT/US2001/050559 WO2002057240A1 (en) 2000-12-22 2001-12-21 Substituted triazole diamine derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
SK9062003A3 true SK9062003A3 (en) 2004-04-06

Family

ID=22977396

Family Applications (1)

Application Number Title Priority Date Filing Date
SK906-2003A SK9062003A3 (en) 2000-12-22 2001-12-21 Substituted triazole diamine derivatives as kinase inhibitors

Country Status (23)

Country Link
US (2) US6924302B2 (cs)
EP (1) EP1355889B1 (cs)
CN (1) CN100357278C (cs)
AT (1) ATE328874T1 (cs)
BG (2) BG107959A (cs)
BR (1) BR0116792A (cs)
CA (1) CA2432870A1 (cs)
CZ (1) CZ20031941A3 (cs)
DE (1) DE60120494T2 (cs)
DK (1) DK1355889T3 (cs)
ES (1) ES2266313T3 (cs)
HU (1) HUP0303868A3 (cs)
IL (1) IL156584A0 (cs)
MX (1) MXPA03005777A (cs)
NO (1) NO20032848L (cs)
NZ (1) NZ526624A (cs)
PL (1) PL363316A1 (cs)
PT (1) PT1355889E (cs)
RU (1) RU2274639C2 (cs)
SK (1) SK9062003A3 (cs)
WO (1) WO2002057240A1 (cs)
YU (1) YU51803A (cs)
ZA (1) ZA200305619B (cs)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017997A1 (ja) * 2002-08-06 2004-03-04 Toray Industries, Inc. 腎疾患治療又は予防剤及び腎疾患の診断方法
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
CA2525928A1 (en) 2003-05-13 2005-01-06 Depuy Spine, Inc. A method of treating degenerative disc disease
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
TW200514776A (en) 2003-08-06 2005-05-01 Vertex Pharma Aminotriazole compounds useful as inhibitors of protein kinases
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
DE10356579A1 (de) * 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
US20090270456A1 (en) * 2004-01-09 2009-10-29 Masaichi Hasegawa Novel chemical compounds
WO2005072826A2 (en) 2004-01-21 2005-08-11 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
AU2005212218A1 (en) * 2004-02-11 2005-08-25 Janssen Pharmaceutica, N.V. Process for the preparation of substituted triazole compounds
US7888380B2 (en) * 2004-10-08 2011-02-15 Janssen Pharmaceutica, N.V. 1,2,4-Triazolylaminoaryl (heteroaryl) sulfonamide derivatives
ATE485042T1 (de) 2004-10-21 2010-11-15 Vertex Pharma Triazole als hemmer von proteinkinasen
DE102004055998A1 (de) * 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
EP1922310A2 (en) * 2005-09-07 2008-05-21 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
US7879887B2 (en) 2006-06-29 2011-02-01 Nissan Chemical Industries, Ltd. α-amino acid derivatives and medicaments containing the same as an active ingredient
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
DE102006054205A1 (de) * 2006-11-15 2008-05-29 Rheinische Friedrich-Wilhelms Universität Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit
CA2695613A1 (en) 2006-12-19 2008-06-26 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
AU2007342005A1 (en) * 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors
PL2114955T3 (pl) * 2006-12-29 2013-06-28 Rigel Pharmaceuticals Inc Triazole podstawione mostkowanym bicyklicznym arylem oraz mostkowanym bicyklicznym heteroarylem użyteczne jako inhibitory Axl
PL2078010T3 (pl) 2006-12-29 2014-07-31 Rigel Pharmaceuticals Inc Triazole podstawione policyklicznym heteroarylem użyteczne jako inhibitory Axl
US7872000B2 (en) 2006-12-29 2011-01-18 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as Axl inhibitors
WO2008083356A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
CN101827836B (zh) 2007-10-18 2014-02-19 詹森药业有限公司 三取代的1,2,4-三唑化合物
JP5635909B2 (ja) * 2007-10-26 2014-12-03 ライジェル ファーマシューティカルズ, インコーポレイテッド Axl阻害剤として有用な多環アリール置換トリアゾール及び多環ヘテロアリール置換トリアゾール
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
AU2009216851B2 (en) 2008-02-22 2013-11-07 F. Hoffmann-La Roche Ag Modulators for amyloid beta
US8778974B2 (en) 2008-03-19 2014-07-15 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 triazoles
EP2280945B1 (en) 2008-05-09 2014-09-03 Janssen Pharmaceutica, N.V. Trisubstituted pyrazoles as acetylcholine receptor modulators
JP5592884B2 (ja) 2008-07-09 2014-09-17 ライジェル ファーマシューティカルズ, インコーポレイテッド Axl阻害剤として有用な多環式ヘテロアリール置換トリアゾール
JP5613156B2 (ja) * 2008-07-09 2014-10-22 ライジェル ファーマシューティカルズ, インコーポレイテッド Axl阻害剤として有用な架橋二環ヘテロアリール置換トリアゾール
MX2011003246A (es) 2008-10-09 2011-04-21 Hoffmann La Roche Moduladores de beta amiloide.
EP2355817A1 (en) * 2008-11-10 2011-08-17 F. Hoffmann-La Roche AG Heterocyclic gamma secretase modulators
PT2387395E (pt) 2009-01-16 2015-02-04 Rigel Pharmaceuticals Inc Inibidores de axl para utilização em terapia de combinação para prevenir, tratar ou gerir cancro metastático
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US20140010783A1 (en) * 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
WO2014071298A1 (en) * 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
EP2964633B1 (en) * 2013-03-05 2017-04-19 F. Hoffmann-La Roche AG Antiviral compounds
CN105102449B (zh) * 2013-03-06 2017-06-13 豪夫迈·罗氏有限公司 抗病毒化合物
WO2018175670A1 (en) 2017-03-22 2018-09-27 The Research Foundation For The State University Of New York Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same
US12110278B2 (en) * 2020-10-13 2024-10-08 Yale University Selective JAK2 pseudokinase ligands and methods of use
EP4423090A2 (en) * 2021-10-26 2024-09-04 Vasocardea, Inc. Antagonists of gpr39 protein
CN114292243B (zh) * 2022-01-12 2023-11-21 中山大学 一种三唑类衍生物或其药学上可接受的盐及其制备方法和应用
CN115433222A (zh) * 2022-09-20 2022-12-06 五邑大学 一种2-(偕二氟丙烯)苯甲酰胺类化合物的制备方法及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2352944A (en) 1942-07-04 1944-07-04 Gen Electric Triazole derivatives
NL301383A (cs) * 1962-12-06
US4727022A (en) * 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5196351A (en) * 1987-09-30 1993-03-23 Beckman Instruments, Inc. Bidentate conjugate and method of use thereof
HU206095B (en) * 1989-10-25 1992-08-28 Egyt Gyogyszervegyeszeti Gyar Process for producing triazolylcarboxylc acid hydrazie and semicarbazide derivatives and pharmaceutical compositions comprising same
HU206096B (en) * 1989-11-24 1992-08-28 Egyt Gyogyszervegyeszeti Gyar Process for producing triazolylcarboxylic acid thioamide derivatives and pharmaceutical compositions comprising same
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
ES2223040T3 (es) * 1991-04-10 2005-02-16 The Scripps Research Institute Bibliotecas de receptor heterodimerilo que usan fagemidos.
WO1993005027A1 (fr) * 1991-09-02 1993-03-18 Yamanouchi Pharmaceutical Co., Ltd. Amine tertiaire triazolylee ou un sel de celle-ci
US5543507A (en) * 1992-03-05 1996-08-06 Isis Pharmaceuticals, Inc. Covalently cross-linked oligonucleotides
US5362859A (en) * 1992-07-27 1994-11-08 Sepracor, Inc. High-capacity affinity supports and methods for the preparation and use of same
US5512435A (en) * 1993-02-05 1996-04-30 Renschler; Markus F. Receptor-binding antiproliferative peptides
US5750545A (en) * 1993-07-23 1998-05-12 The Green Cross Corporation Triazole derivative and pharmaceutical use thereof
US5698401A (en) * 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
ATE332896T1 (de) * 1997-10-27 2006-08-15 Agouron Pharma 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin- abhängiger kinasen
GB9918180D0 (en) 1999-08-02 1999-10-06 Smithkline Beecham Plc Novel compositions

Also Published As

Publication number Publication date
BR0116792A (pt) 2004-02-17
US20050182116A1 (en) 2005-08-18
CN1575284A (zh) 2005-02-02
DK1355889T3 (da) 2006-10-09
BG107959A (bg) 2004-12-30
DE60120494T2 (de) 2006-12-21
NO20032848D0 (no) 2003-06-20
NO20032848L (no) 2003-08-20
US6924302B2 (en) 2005-08-02
RU2274639C2 (ru) 2006-04-20
HUP0303868A2 (hu) 2004-03-01
ZA200305619B (en) 2004-10-21
RU2003118448A (ru) 2005-01-27
CZ20031941A3 (cs) 2004-08-18
NZ526624A (en) 2005-07-29
US20040077699A1 (en) 2004-04-22
YU51803A (sh) 2006-05-25
DE60120494D1 (de) 2006-07-20
BG107985A (bg) 2004-11-30
HUP0303868A3 (en) 2008-03-28
EP1355889B1 (en) 2006-06-07
CA2432870A1 (en) 2002-07-25
ATE328874T1 (de) 2006-06-15
IL156584A0 (en) 2004-01-04
PL363316A1 (en) 2004-11-15
HK1057373A1 (en) 2004-04-02
CN100357278C (zh) 2007-12-26
US7317031B2 (en) 2008-01-08
PT1355889E (pt) 2006-09-29
MXPA03005777A (es) 2005-02-14
WO2002057240A1 (en) 2002-07-25
EP1355889A1 (en) 2003-10-29
ES2266313T3 (es) 2007-03-01

Similar Documents

Publication Publication Date Title
SK9062003A3 (en) Substituted triazole diamine derivatives as kinase inhibitors
AU2016206247B2 (en) Multisubstituted aromatic compounds as inhibitors of thrombin
AU763356B2 (en) Fused-ring compounds and use thereof as drugs
TWI457333B (zh) 嗒酮化合物
US8273738B2 (en) Imidazole derivatives
JP4911866B2 (ja) ファルネシルトランスフェラーゼ阻害剤としてのファルネシルトランスフェラーゼを阻害するキノリンおよびキナゾリン誘導体
KR20030036735A (ko) 축합환 화합물 및 그 의약 용도
WO2001068585A1 (en) Novel amide compounds
BG65207B1 (bg) Производни на хетероциклен карбамид и използването им за инхибиране на raf киназа
JP2011526616A (ja) 化学化合物
KR20140124398A (ko) 오렉신 수용체 길항제로서 치환된 프롤린 / 피페리딘
JP2007509173A (ja) インドリノン誘導体類及び疾病状態、例えば癌の処理へのそれらの使用
EP2107054A1 (en) Antiproliferative compounds and therapeutic uses thereof
CN105814037B (zh) 作为丙酮酸脱氢酶激酶的抑制剂的n1-(3,3,3-三氟-2-羟基-2-甲基丙酰基)-哌啶衍生物
US20090156646A1 (en) Pyridylphenol compound and use thereof
CN101233128B (zh) 在糖尿病治疗中用作glk激活剂的杂芳基苯甲酰胺衍生物
TW202031644A (zh) 苯并咪唑衍生物
AU2002249872B2 (en) Substituted triazole diamine derivatives as kinase inhibitors
EP1712550A2 (en) Substituted triazole diamine derivatives as kinase inhibitors
AU2002249872A1 (en) Substituted triazole diamine derivatives as kinase inhibitors
KR100501424B1 (ko) 축합환 화합물 및 그 의약 용도
HK1057373B (en) Substituted triazole diamine derivatives as kinase inhibitors

Legal Events

Date Code Title Description
FC9A Refused patent application